|
|
Programme
Indicated times are in CEST timezone.
| Sunday August 29, 2021 |
EFMC-ISMC 2021 Opening
Morning Session |
|
| EFMC-ISMC 2021 Opening Ceremony
|
|
|
| 10:00 | Opening Address by EFMC-ISMC 2021 Chairman |
Prof. Karl-Heinz ALTMANN
(ETH ZÜRICH, Zürich, Switzerland) |
|
| Address by EFMC president |
Prof. Rui MOREIRA
(UNIVERSITY OF LISBON, Lisbon, Portugal) |
|
| 10:15 | Opening Lecture
Creating the Next Generation of Therapeutics - Medicinal Chemistry Unleashed (PL001) |
Dr Karin BRINER
(NOVARTIS, South San Francisco, United States) |
|
|
THE NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
Award Ceremony |
|
|
| 10:55 | Award Ceremony presided by EFMC Past-President |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
|
| Nauta Award Presentation |
Prof. Henk TIMMERMAN (VU UNIVERSITY AMSTERDAM, Oegstgeest, The Netherlands)
Dr Andele NAUTA (PROF. DR. W. TH NAUTA STICHTING, The Netherlands) |
|
| 11:05 | The Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Award Lecture
Partial Agonism in the Picture (AL001) |
Prof. Ad P. IJZERMAN
(LEIDEN UNIVERSITY, Leiden, The Netherlands) |
|
| 11:45 | End of Morning Session |
|
|
|
EFMC-ISMC 2021 Opening
Afternoon Session |
|
| 13:00 | THE UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
Award Ceremony |
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Dr Adrian HALL (UCB PHARMA S.A., Braine-l'Alleud, Belgium) |
|
| 13:10 | The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Award Lecture
Experiences & Future Direction for Medicinal Chemistry in Cardiovascular, Renal and Metabolism Diseases (AL002) |
Dr Malin LEMURELL
(ASTRAZENECA, Gothenburg, Sweden) |
|
| 13:50 | THE PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
Award Ceremony |
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Dr Josep Jr. PROUS (PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, Barcelona, Spain) |
|
| 14:00 | The Prous Institute - Overton and Meyer Award for New technologies in Drug Discovery
Award Lecture
De Novo Drug Design with Machine Intelligence (AL003) |
Prof. Gisbert SCHNEIDER
(ETH ZÜRICH, Zürich, Switzerland) |
|
| 14:40 | EFMC Fellows Ceremony |
Prof. Rui MOREIRA (UNIVERSITY OF LISBON, Lisbon, Portugal)
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| |
|
|
| 15:15 | End of the Day |
|
| Monday August 30, 2021 |
| Plenary Session |
|
| Chair |
Dr Karl-Heinz BARINGHAUS
(SANOFI, Frankfurt, Germany) |
| 09:30 | Medicinal Chemistry: More than Ever (PL002) |
Dr Jean-Paul CLOZEL
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland) |
|
|
Session 1 'Chemical Biology'
Molecular Imaging Tools for Chemical Biology
| Session 2 'Technologies'
Novel Strategies and Methods for Drug Discovery and Development
(CPA Session) | Session 3 'Drug Discovery Projects'
Chemical Tools and Drug Discovery for Neuroinflammation
(EuChemS Session)
|
| Session 1%s%Chemical Biology | Session 2%s%Technologies | Session 3%s%DD Projects |
| 10:15 | Session Chair |
Dr Valle PALOMO
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain) |
|
| 10:15 | Session Chair |
Prof. Ke DING
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES, Shanghai, China) |
|
| 10:15 | Session Chair |
Dr Sonsoles MARTIN-SANTAMARIA
(CIB-CSIC, Madrid, Spain) |
| |
|
| 10:20 | Along the Allostery Stream: Recent Advances in Computational Methods for Allosteric Drug Discovery (LE005) |
Prof. Jian ZHANG
(SHANGHAI JIAO TONG UNIVERSITY, Shanghai, China) |
|
| 10:20 | Microglia in Neuroinflammation: an Intriguing Target towards Neuroprotection and Neuroregeneration (LE009) |
Prof. Barbara MONTI
(UNIVERSITY OF BOLOGNA, Bologna, Italy) |
|
| 11:00 | Chemical Tools to Study Redox Biology (LE002) |
Prof. Pablo RIVERA FUENTES
(EPF LAUSANNE, Lausanne, Switzerland) |
|
| 11:00 | Molecular Glue Design for Targeted Cancer Therapy (LE006) |
Dr Xiangbing QI
(TSINGHUA UNIVERSITY | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCE, Beijing, China) |
|
| 11:00 | Development of Fluorinated PET Tracers for Imaging of α1 Receptors in the Brain (LE010) |
Prof. Bernhard WÜNSCH
(UNIVERSITY OF MÜNSTER, Münster, Germany) |
|
| 11:20 | Sensing Enzymatic Activity with Quantum Dots in Patient-Derived Neurodegenerative Disease Models (LE003) |
Dr Valle PALOMO
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain) |
|
| 11:20 | Discovery of New SARS-COV-2 MPRO Inhibitors With Potent in vitro and In vivo Antiviral Activity (LE007) |
Prof. Shengyong YANG
(SICHUAN UNIVERSITY, Sichuan, China) |
|
| 11:20 | Boosting the Resolution of Inflammation Through Formyl Peptide Receptor 2 (FPR2) Agonists as a Novel Strategy in Neuroinflammation-associated Central Nervous System Disorders (LE011) |
Prof. Enza LACIVITA
(UNIVERSITÀ DEGLI STUDI DI BARI, Bari, Italy) |
|
| 11:40 | Pattern-generating Fluorescent Molecular Probes for Chemical Biology (LE004) |
Dr Leila MOTIEI
(WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel) |
|
| 11:40 | Development of A New Target Identification System for Small Molecules in Trypanosoma Brucei Parasites (LE008) |
Ms Suzanne Sherihan SAHRAOUI
(UNIVERSITY OF GENEVA, Geneva, Switzerland) |
|
| 11:40 | Small Molecule Degradeers Targeting Folding Intermediates: the Prion Protein Case Study (LE012) |
Dr Andrea ASTOLFI
(UNIVERSITY OF PERUGIA, Perugia, Italy) |
|
|
| 12:00 | End of morning session |
|
| Company Workshop |
|
| 12:30 | Company Workshop
Schrödinger
LiveDesign: a Collaborative Environment for Real-world Drug Discovery Workflows |
|
|
|
| 13:15 | Poster Session 1, Exhibition & Networking |
|
Session 4 'Chemical Biology'
Photochemistry in Drug Discovery: Photopharmacology, Phototoxicity and Synthesis
(ACSMEDI Session) | Session 5 'Technologies'
Cryo-EM as an Emerging Tool for Small-Molecule Drug Discovery
| Session 6 'Drug Discovery Projects'
Next Generation Drugs for Heart Failure
|
| Session 4%s%Chemical Biology | Session 5%s%Technologies | Session 6%s%DD Projects |
| 15:30 | Session Chairs |
Mr Timothy J. HENDERSON (MERCK & CO, Boston, United States)
Dr Amjad ALI (MERCK & CO. INC., Kenilworth, United States) |
|
| 15:30 | Session Chair |
Dr Jean-Paul RENAUD
(URANIA THERAPEUTICS, Ostwald, France) |
|
| 15:30 | Session Chair |
Dr Alleyn T. PLOWRIGHT
(WREN THERAPEUTICS LTD, Cambridge, United Kingdom) |
|
| 15:35 | Photopharmacology: Towards Light-Controlled Therapy (LE013) |
Dr Wiktor SZYMANSKI
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands) |
|
| 15:35 | Cryo-EM in GPCR Structure Based Drug Discovery (LE017) |
Dr Stacey SOUTHALL
(SOSEI HEPTARES, Cambridge, United Kingdom) |
|
| 15:35 | Identification of Potent and Long Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases (LE021) |
Dr Sergio MALLART
(SANOFI R&D, CHILLY MAZARIN, France) |
|
| 16:15 | Mapping Cell-Cell Interactions in Tumor Microenvironment via Photocatalytic Proximity Labeling (LE014) |
Dr Niyi FADEYI
(MERCK & CO, Cambridge, United States) |
|
| 16:15 | Allosteric Regulation of GTP Cyclohydrolase I (LE018) |
Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany) |
|
| 16:15 | MAP4K4 Inhibitors For The Suppression Of Cardiac Muscle Cell Death (LE023) |
Dr Gary NEWTON
(THE INSTITUTE OF CANCER RESEARCH, London , United Kingdom) |
|
| 16:35 | Azaaurones as Novel Chemotypes Against Mycobacterium Tuberculosis: SAR ADME Profiling and Photo-Switching Properties (LE015) |
Mr André CAMPANICO
(I.MED.ULISBOA - FFULISBOA, Lisboa, Portugal) |
|
| 16:35 | The Role of Cryo-EM in Fragment-Based Drug Discovery (LE019) |
Dr Judith REEKS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
|
|
| 16:55 | In vivo Adrenergic Modulation with Photopharmacology (LE016) |
Dr Davia PRISCHICH
(INSTITUTE FOR BIOENGINEERING OF CATALONIA (IBEC) , Barcelona, Spain) |
|
| 16:55 | Structure Based Drug Discovery Targeting Helicobacter Pylori, Using Cryo-EM (LE020)
|
Dr Eva CUNHA
(UNIVERSITY OF OSLO & OSLO UNIVERSITY HOSPITAL, OSLO, Norway) |
|
| 16:55 | Discovery of Aficamten (CK-274): A Novel, Small Molecule, Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathies (HCM) (LE022)
|
Dr Grace CHUANG
(CYTOKINETICS, South San Francisco, United States) |
|
|
Session 7.1.
First Time Disclosures (Part I) |
|
| Session Chair |
Dr Cornelia ZUMBRUNN
(IDORSIA PHARMACEUTICALS LTD., Allschwil, Switzerland) |
|
| 17:15 | Design and Preclinical Characterization Program Towards BAY 2433334, an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders (LE025) |
Dr Susanne ROEHRIG
(BAYER HEALTHCARE, Wuppertal, Germany) |
|
| 17:45 | First Time Disclosure of BI 1265162, an ENaC Inhibitor for the Treatment of Cystic Fibrosis (LE026) |
Dr Jörg KLEY
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany) |
|
| 18:15 | Discovery of the Clinical Candidate AZD4604, a Potent and Selective Janus Kinase 1 Inhibitor, as an Inhaled Treatment for Respiratory Disease (LE027) |
Dr Magnus NILSSON
(ASTRAZENECA, Mölndal, Sweden) |
|
|
| 18:45 | End of the Day |
|
| Tuesday August 31, 2021 |
| EFMC Prize Ceremony & Lectures 2020 |
|
|
|
| 09:35 | The 2020 EFMC Prize for a Young Medicinal Chemist in Industry
Discovery of Potent Selective GABAA Alpha5 Positive Allosteric Modulators (PAMs) for the treatment of neurological disorders (PR001) |
Dr Giuseppe CECERE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| |
|
|
Session 8 'Chemical Biology'
Chemical Probes for Target Discovery and Validation
| Session 9 'Technologies'
Innovative Synthesis for Medicinal Chemistry
| Session 10 'Drug Discovery Projects'
Addressing Neglected and Emerging Viral Diseases with Small Molecules
(AFMC Session) |
| Session 8%s%Chemical Biology | Session 9%s%Technologies | Session 10%s%DD Projects |
| 10:15 | Session Chair |
Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary) |
|
| 10:15 | Session Chair |
Prof. Cristina NEVADO
(UNIVERSITY OF ZURICH, Zurich, Switzerland) |
|
| 10:15 | Session Chair |
Prof. Esin AKI-YALCIN
(ANKARA UNIVERSITY, Ankara, Turkey) |
|
| 10:20 | Chemical Probes to Explore Cancer Biology and Validate Drug Targets (LE028) |
Prof. Paul WORKMAN
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom) |
|
|
| 10:20 | Discovery of a Novel Class of Small Molecule Dengue Virus Inhibitors (LE036) |
Dr Tim JONCKERS
(JANSSEN, Beerse, Belgium) |
|
| 11:00 | Chemical Probes to Study Lipid Signaling (LE029) |
Prof. Mario VAN DER STELT
(LEIDEN UNIVERSITY, Leiden, The Netherlands) |
|
| 11:00 | Innovative DNA-based Asymmetric Catalysis (LE033) |
Dr Stellios ARSENIYADIS
(QUEEN MARY UNIVERSITY OF LONDON, London, United Kingdom) |
|
| 11:00 | Antivirals Against Chikungunya Virus: Analyzing the Current Situation to Identify New Opportunities (LE037) |
Prof. Maria-Jesus PÉREZ-PÉREZ
(INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain) |
|
| 11:20 | Discovery of MRK-740, a First-in-class, Potent, Selective and Cell Active PRDM9 Chemical Probe (LE030) |
Dr Christian FISCHER
(MERCK, SHARP & DOHME, Boston, United States) |
|
| 11:20 | Scaffold-Assisted Peptide Cyclizations: Towards Protein Mimics (LE034) |
Prof. Jan VAN MAARSEVEEN
(UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands) |
|
| 11:20 | Artificial Intelligence for Emerging and Neglected Diseases Drug Discovery (LE038) |
Prof. Carolina H. ANDRADE
(FEDERAL UNIVERSITY OF GOIAS , Goiânia, Brazil) |
|
| 11:40 | Quenched Activity-based Probes as New Chemical Tools to Analyse Resistance to Antibiotics (LE031) |
Ms Rita FÉLIX
(IMED.ULISBOA - RESEARCH INSTITUTE FOR MEDICINES, Lisbon, Portugal) |
|
| 11:40 | Synthesis of New Building Blocks from the Chemical Universe Database GDB (LE035) |
Ms Aline CARREL
(UNIVERSITY OF BERN, Bern, Switzerland) |
|
| 11:40 | Innovative Dihydroorotate Dehydrogenase Clinical Ready Inhibitors as Pan-Coronavirus Antivirals: Targeting the Unexpected with Innovation (LE039) |
Prof. Marco Lucio LOLLI
(UNIVERSITY OF TURIN, Torino, Italy) |
|
|
| 12:00 | End of morning session |
|
| Company Workshop 1 | Company Workshop 2 |
| Chemical%s%Computing Group | WuXi AppTec |
| 12:30 | Chemical Computing Group: Designing Molecules in the Binding Site
|
|
|
| 12:30 | WuXi AppTec: DEL Screening Technology as an Enabling Tool for Medicinal Chemists |
|
|
|
| 13:15 | Poster Session 2, Exhibition & Networking |
|
Session 11 'Chemical Biology'
Chemical Approaches to Stem Cell Differentiation
(ICBS Session) | Session 12 'Technologies'
Expanding Chemical Space through AI - Linking Synthesis Prediction and Automation
| Session 13 'Drug Discovery Projects'
Breathing Life into Inhaled Drug Discovery: Challenges and Breakthroughs to the Clinic
(ACSMEDI Session)
|
| Session 11%s%Chemical Biology | Session 12%s%Technologies | Session 13%s%DD Projects |
| 15:30 | Session Chair |
Prof. Colin POUTON
(MONASH UNIVERSITY, Clayton, Australia) |
|
| 15:30 | Session Chair |
Dr Ola ENGKVIST
(ASTRAZENECA, Mölndal, Sweden) |
|
| 15:30 | Session Chair |
Dr Nicole GOODWIN
(GSK, King of Prussia, United States) |
| |
|
| 15:35 | AI Assisted and Automated Chemical Synthesis (LE044) |
Prof. Klavs F. JENSEN
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States) |
|
| 15:35 | Inhaled New Modalities in Respiratory Disease: Past, Present, Future (LE048) |
Dr Werngard CZECHTIZKY
(ASTRAZENECA, Mölndal, Sweden) |
|
| 16:15 | Discovery of Small Molecules to Manipulate Cell Fate in vivo: Towards New Therapies for Degenerative Diseases (LE041) |
Prof. Angela RUSSELL
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
|
| 16:15 | Universal Synthesis Machines and Chemputation (LE045) |
Prof. Leroy CRONIN
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom) |
|
| 16:15 | Discovery of Novel Inhaled PI3Kd Inhibitor by Lung Retention Optimisation (LE049) |
Dr Montse ERRA SOLA
(ALMIRALL, S.A., Barcelona, Spain) |
|
| 16:35 | Probing Embryonic Mesodermal Differentiation Enables Identification of Small Molecule Bone Morphogenetic Protein Activators (LE042) |
Prof. Dennis SCHADE
(CHRISTIAN-ALBRECHTS-UNIVERSITY OF KIEL, Kiel, Germany) |
|
| 16:35 | AI in the Lab: Automating Chemical Synthesis. Where Next From Here? (LE046) |
Dr Teodoro LAINO
(IBM RESEARCH EUROPE, Rueschlikon, Switzerland) |
|
| 16:35 | Introduction to Preclinical Inhaled Drug Dosing and its Application to Measure the Therapeutic Index of Inhaled Steroids (LE050) |
Dr Jonathan PHILLIPS
(AMGEN, Newbury Park, United States) |
|
| 16:55 | Potential of Stem Cell Technology in Discovery of Drugs for Neurodegenerative Diseases (LE043) |
Prof. Colin POUTON
(MONASH UNIVERSITY, Clayton, Australia) |
|
| 16:55 | Progress and Limitations in Exploring the Chemical Space with AI (LE047) |
Dr Ola ENGKVIST
(ASTRAZENECA, Mölndal, Sweden) |
|
| 16:55 | Design and Development of Inhaled Molecules to Target the Pulmonary Vasculature (LE051) |
Dr Duncan SHAW
(NOVARTIS, Cambridge, United States) |
|
|
Session 7.2.
First Time Disclosures (Part II) |
|
| 17:15 | Session Chair |
Dr Antonia F. STEPAN
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland) |
| 17:15 | Discovery of an Oral, RO5 Compliant, Interleukin 17a Protein-Protein Interaction Modulator for the Treatment of Psoriasis and other Inflammatory Diseases (LE052) |
Mr Kevin DACK
(LEO PHARMA, Ballerup, Denmark) |
| 17:45 | Insights to the Discovery and Design of Ataxia Telangiectasia Mutated (ATM) Kinase inhibitors M3541 and M4076 with Strong Anti-tumor Efficacy in Combination Therapy Approaches (LE053) |
Dr Thomas FUCHSS
(MERCK KGAA, Darmstadt, Germany) |
| 18:15 | Discovery of JDQ443 a Structurally Unique, Highly Potent, Selective and Orally Bioavailable KRASG12C Covalent Inhibitor (LE054) |
Dr Simona COTESTA
(NOVARTIS, Basel, Switzerland) |
|
|
| 18:45 | End of the Day |
|
| Wednesday September 1, 2021 |
| EFMC Prize Ceremony & Lectures 2021 |
|
|
|
| 09:35 | The 2021 EFMC Prize for a Young Medicinal Chemist in Industry
Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (PR003) |
Dr Niall ANDERSON
(GLAXOSMITHKLINE, Hertfordshire, United Kingdom) |
|
| 09:55 | The 2021 EFMC Prize for a Young Medicinal Chemist in Academia
COVID Moonshot – Crowdsourcing a Covid-19 Cure (PR004) |
Dr Nir LONDON
(THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel) |
|
|
Session 14 'Chemical Biology'
Carbohydrate Recognition and Drug Design
| Session 15 'Technologies'
Application of Artificial Intelligence in Drug Discovery Projects | Session 16 'Drug Discovery Projects'
New Strategies and Agents for Targeting Gram-Negative Pathogens
|
| Session 14%s%Chemical Biology | Session 15%s%Technologies | Session 16%s%DD Projects |
| 10:15 | Session Chair |
Dr Alexander TITZ
(HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL SCIENCES, Saarbrücken, Germany) |
|
| 10:15 | Session Chair |
Dr Christopher SWAIN
(CAMBRIDGE MEDCHEM CONSULTING, Duxford, United Kingdom) |
|
|
| 10:20 | C-type Lectin Receptors as Drug Targets (LE055) |
Dr Christoph RADEMACHER
(UNIVERSITY OF VIENNA, Vienna, Austria) |
|
| 10:20 | Artificial Intelligence in Chemical Biology and Drug Discovery - Data, Applications, and Illusions (LE059)
|
Prof. Andreas BENDER
(UNIVERSITY OF CAMBRIDGE, United Kingdom) |
|
| 10:20 | Therapies for Gram-Negative Bacterial Infections: New Approaches and Further Generations of Existing Series (LE063) |
Dr Mike DAWSON
(MIKE DAWSON ANTIMICROBIAL RESEARCH CONSULTANCY LTD., Stevenage, United Kingdom) |
|
| 11:00 | Design, Synthesis, and Development of Lectin Ligand Mimetics (LE056) |
Prof. Ulf NILSSON
(LUND UNIVERSITY, Lund, Sweden) |
|
| 11:00 | Augmenting Drug Hunters with Generative Chemistry Models (LE060) |
Dr Nadine SCHNEIDER
(NOVARTIS, Basel, Switzerland) |
|
| 11:00 | Tethered Macrocyclic Peptides, a Novel Antibiotic Class Targeting Acinetobacter Baumannii (LE064) |
Dr Patrizio MATTEI
(ROCHE INNOVATION CENTER BASEL, Basel, Switzerland) |
|
| 11:20 | Lectins from Pathogens: From Structural Glycobiology to Antiadhesive Strategies (LE057) |
Dr Anne IMBERTY
(CNRS/CERMAV, Grenoble, France) |
|
| 11:20 | Navigating Chemical Space by Artificial Intelligence (LE061) |
Dr Gerhard HESSLER
(SANOFI-AVENTIS DEUTSCHLAND, Frankfurt am Main, Germany) |
|
| 11:20 | Discovery of Submicromolar Inhibitors of the Virulence Factor LASB from Pseudomonas Aeruginosa Using Rational Design (LE065) |
Prof. Anna K. H. HIRSCH
(HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany) |
|
| 11:40 | Development of Glycomimetic Collectin-11 Antagonists to Reduce Complement-Mediated Ischemia-Reperfusion Injuries (LE058) |
Dr Rachel HEVEY
(UNIVERSITÄT BASEL, Basel, Switzerland) |
|
| 11:40 | Generative Recurrent Neural Networks (RNN) for de novo Drug Design (LE062) |
Dr Pooja DESHMUKH
(SAI LIFESCIENCES PVT LIMITED, Hyderabad, India) |
|
| 11:40 | DOTAM-based Sideromycins to Visualize and Treat MDR Bacterial Pathogens in vivo and in vitro (LE066) |
Mr Carsten PEUKERT
(HELMHOLTZ CENTRE FOR INFECTION RESEARCH, Braunschweig, Germany) |
|
|
| 12:00 | End of morning sesssion |
|
| Company Workshops 1 | Company Workshops 2 |
| Charles River%s%workshop | NovAliX%s%workshop |
| 12:30 | Charles River: Developing Inhaled Drugs for Respiratory Diseases: A Medicinal Chemistry Perspective |
|
|
| 12:30 | NovAliX: DNA-Encoded Library Technology: Strengths and Development Opportunities |
|
|
|
| 13:15 | Poster Session 3, Exhibition & Networking |
|
Session 17 'Chemical Biology'
Small Molecules Targeting RNA Function and Processing | Session 18
Highlights of Medicinal Chemistry
| Session 19 'Drug Discovery Projects'
Tissue and Cell Specific Drug Delivery
(EUFEPS Session) |
| Session 17%s%Chemical Biology | Session 18 | Session 19%s%DD Projects |
| 15:30 | Session Chair |
Dr Maria DUCA
(UNIVERSITY OF CÔTE D'AZUR, Nice, France) |
|
| 15:30 | Session Chair |
Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium) |
|
| 15:30 | Session Chair |
Prof. Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France) |
|
| 15:35 | Targeting RNA With Drug-Like Small Molecules (LE067) |
Dr Jennifer PETTER
(ARRAKIS THERAPEUTICS, Waltham, United States) |
|
| 15:35 | Discovery and Development of a Mkk-4 Inhibitors to Increase Liver Regeneration (LE071) |
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany) |
|
| 15:35 | Antibody-Drug Conjugates (ADC) and Small Molecule-Drug Conjugates (SMDC): a Comparative Evaluation (LE075) |
Prof. Dario NERI
(ETH ZÜRICH, Zürich, Switzerland) |
|
| 16:15 | Drugging RNA Modifying Enzymes - METTL3 Inhibitors (LE068) |
Dr David HARDICK
(STORM THERAPEUTICS LTD, Cambridge, United Kingdom) |
|
| 15:55 | Targeting Oncogenic BRAF Using a Novel Allosteric Site (LE072) |
Prof. Evripidis GAVATHIOTIS
(ALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States) |
|
| 16:15 | Nucleic Acids as Household Medicine: Living in The World of RNA Therapeutics (LE076) |
Dr Muthiah MANOHARAN
(ALNYLAM PHARMACEUTICALS, Cambridge, United States) |
|
| 16:35 | Modulating Viral RNAS with Amiloride Small Molecules (LE070)
|
Prof. Amanda HARGROVE
(DUKE UNIVERSITY, Durham, NC, United States) |
|
| 16:15 | Furan-Oxidation Mediated Technology: from in vitro Analysis of Protein-Protein Interactions to GPCR-Ligand Interactions on Live Cells (LE073) |
Dr Laia MIRET CASALS
(GHENT UNIVERSITY, Gent, Belgium) |
|
| 16:35 | Omics-Based Development of Nanomedicines for Safe and Effective Drug Delivery in Cancer (LE077) |
Prof. Erem BILENSOY
(HACETTEPE UNIVERSITY, Ankara, Turkey) |
|
| 16:55 | Splice-Switching Small Molecules as Inducers of Apoptosis (LE069) |
Ms Emma CAMPBELL
(UNIVERSITY OF STRATHCLYDE, Glasgow, United Kingdom) |
|
| 16:35 | LNP023: Discovery and Synthesis of a First-In-Class, Oral Factor B Inhibitor for Treatment of Rare Renal and Hematological Diseases (LE074) |
Dr Stefanie FLOHR
(NOVARTIS, Basel, Switzerland) |
|
| 16:55 | Targeting the Specificities of the Tumor Microenvironment for Cancer Therapy and Diagnosis (LE078)
|
Prof. Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France) |
| |
|
| 16:55 | The IUPAC-Richter Prize Lecture
The Discovery of Relpax® and Nurtec ODT® - Two Different Treatments for Migraine Headaches (PR005) |
Dr John E. MACOR
(SANOFI, Natick, United States) |
|
|
|
|
|
| 18:00 | End of the Day |
|
| Thursday September 2, 2021 |
| Plenary Session |
|
| Chair |
Dr Luc VAN HIJFTE
(SYMERES, Nijmegen, The Netherlands) |
| 09:30 | Targeting Protein Scaffolding Function in Kinases (PL004) |
Prof. Stefan KNAPP
(GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany) |
|
|
Session 20
Emerging Topics
| Session 21 'Technologies'
Prodrug Strategies in Drug Design and Discovery | Session 22 'Drug Discovery Projects'
Targeting Fibrotic Diseases with Small Molecules |
| Session 20 | Session 21%s%Technologies | Session 22%s%DD Projects |
| 10:15 | Session Chair |
Prof. Beatriz DE PASCUAL-TERESA
(CEU SAN PABLO UNIVERSITY, Madrid, Spain) |
|
| 10:15 | Session Chairs |
Prof. Bernd CLEMENT (UNIVERSITY OF KIEL, Kiel, Germany)
Prof. Jarkko RAUTIO (UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland) |
|
| 10:15 | Session Chair |
Dr Christian KUTTRUFF
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany) |
|
| 10:20 | Toward a New Therapy for Immune-mediated Tissue Injury (LE079) |
Dr Julie SPICER
(THE UNIVERSITY OF AUCKLAND, Auckland, New Zealand) |
|
| 10:20 | Prodrug Strategies in Medicinal Chemistry (LE084) |
Prof. Jarkko RAUTIO
(UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland) |
|
| 10:20 | Novel Molecular Targets for the Treatment of Fibrosis (LE088) |
Prof. Joerg DISTLER
(UNIVERSITY OF ERLANGEN–NUREMBERG, Erlangen, Germany) |
|
| 10:40 | A Phenotypic Screen Identifies a Small Molecule that Induces Differentiation of AML Cells in vitro and Shows Anti-Tumour Effects in vivo (LE080) |
Dr Laia JOSA CULLERE
(INSTITUTE FOR ADVANCED CHEMISTRY OF CATALONIA (IQAC-CSIC), Barcelona, Spain) |
|
| 11:00 | New Examples for N-Hydroxyamidine Prodrugs (LE085) |
Prof. Bernd CLEMENT
(UNIVERSITY OF KIEL, Kiel, Germany) |
|
| 11:00 | Discovery of GLPG1205, a First in Class GPR84 Antagonist in Phase II Clinical Trial (LE089) |
Dr Romain GOSMINI
(NOVALIX, llkirch-Graffenstaden, France) |
|
| 11:00 | Isoform-selective TAU Tubuline Kinase 1 Inhibitors Reduce TDP-43 Hyperphosphorylation: a New Hope in the Treatment of TDP-43 Proteinopathies (LE081) |
Ms Vanesa NOZAL GARCIA
(CIB - CSIC, Madrid, Spain) |
|
| 11:20 | Neladenoson Bialanate Hydrochloride: a Prodrug Exploration of a Partial Adenosine A1 Agonist (LE086) |
Dr Daniel MEIBOM
(BAYER PHARMA, Wuppertal, Germany) |
|
| 11:20 | Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (LE090) |
Dr James THOMPSON
(GLAXOSMITHKLINE, Stevenage, United Kingdom) |
|
| 11:20 | Target-Templated de novo Design of Drug-like Cyclic Peptides: PD-1/PD-L1 Inhibitors (LE082) |
Mr Salvador GUARDIOLA
(ONA THERAPEUTICS, Barcelona, Spain) |
|
| 11:40 | Targeted (Pro)Drugs for Improved Treatment of Brain Tumors (LE087) |
Dr Kristiina HUTTUNEN
(UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland) |
|
| 11:40 | Discovery of the Highly Potent and Selective S1P2 Antagonist GLPG2938, a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis (LE091) |
Dr Adeline PALISSE
(GALAPAGOS NV, Mechelen, Belgium) |
|
| 11:40 | Discovery of LAS200019, a Novel Topical Jak Inhibitor for the Treatment of Inflammatory Skin Diseases (LE083) |
Dr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain) |
|
|
|
|
| 12:00 | End of morning session |
|
| 13:15 | Poster Session 4, Exhibition & Networking |
|
Session 23 'Chemical Biology'
Target Deconvolution Strategies in Drug Discovery | Session 24 'Technologies'
Biocatalysis & Late Stage Functionalisation
| Session 25 'Drug Discovery Projects'
Recent Advances in Anticancer Drug Discovery |
| Session 23%s%Chemical Biology | Session 24%s%Technologies | Session 25%s%DD Projects |
| 15:30 | Session Chair |
Prof. Paul BRENNAN
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
|
| 15:30 | Session Chair |
Dr Radka SNAJDROVA
(NOVARTIS PHARMA AG, Basel, Switzerland) |
|
| 15:30 | Session Chair |
Prof. Roberto DI SANTO
(SAPIENZA UNIVERSITY OF ROME, Rome, Italy) |
|
| 15:35 | Mechanistic Insights of a CDK9 Inhibitor via Orthogonal Proteomics Methods (LE092) |
Dr Paola CASTALDI
(LIFEMINE THERAPEUTICS, Cambridge, United States) |
|
| 15:35 | Reprogramming Nonribosomal Peptide Biosynthesis (LE096) |
Prof. Donald HILVERT
(ETH ZURICH, ZURICH, Switzerland) |
|
| 15:35 | Targeting Cancer (LE100) |
Prof. Daniel RAUH
(TU DORTMUND, Dortmund, Germany) |
|
| 16:15 | Proteomes in 3D (LE093) |
Prof. Paola PICOTTI
(ETH ZÜRICH, Zürich, Switzerland) |
|
| 16:15 | Flavoenzyme Biocatalysis in Bioorganic and Medicinal Chemistry - Challenges and Opportunities (LE097) |
Prof. Marko D. MIHOVILOVIC
(TU WIEN, Vienna, Austria) |
|
| 16:15 | Structure-Based Optimization and Synthesis of M3258, a Potent and Selective Inhibitor of the Immunoproteasome Subunit LMP7 (beta5i) Demonstrating Strong Efficacy in Multiple Myeloma Models (LE101) |
Dr Markus KLEIN
(MERCK KGAA, Darmstadt, Germany) |
|
| 16:35 | A Novel Bacterial Three-Hybrid System for Target Identification in Bacteria (LE094) |
Ms Radhia EL PHIL
(UNIGE, Geneva , Switzerland) |
|
| 16:35 | Utilization of Fe/α-Ketoglutarate-Dependent Enzymes for Stereocontrolled Functionalization (LE098) |
Prof. Rebecca BULLER
(ZHAW SCHOOL OF LIFE SCIENCES AND FACILITY MANAGEMENT, Wädenswil, Switzerland) |
|
| 16:35 | Magic in the Moonlight: Our Contribution to the Development of IDO1 Inhibitors for Cancer Immunotherapy (LE102) |
Prof. Tracey PIRALI
(UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy) |
|
| 16:55 | EFMC-YMCS Presentation Prize
Design and Synthesis of Chemical Tools to Probe the Function of TRIM33 (LE095) |
Ms Jessica REYNOLDS
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
|
| 16:55 | Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using Polycyps Enzymes (LE099) |
Mr Frank SCHEFFLER
(HYPHA DISCOVERY LTD, Abingdon, United Kingdom) |
|
| 16:55 | Design and Optimization of a First-in-class NACK Inhibitor: A Novel Path to Notch Inhibition (LE103) |
Dr Tanya KELLEY
(UNIVERSITY OF MIAMI, Miami, United States) |
|
|
THE KLAUS GROHE AWARD 2020
Award Ceremony |
|
| 17:15 | Laudatio |
Prof. Daniel RAUH
(TU DORTMUND, Dortmund, Germany) |
|
| 17:15 | Award Ceremony - GDCh President |
Prof. Peter R. SCHREINER
(JUSTUS-LIEBIG UNIVERSITY, D-35392 Giessen, Germany) |
| |
|
|
| EFMC-ISMC Closing Ceremony |
|
| 18:05 | Closing Remarks, Poster Prizes and Welcome to EFMC-ISMC 2022 |
|
|
|
|
